Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Lannett Company, Inc. (LCI)

0.5744   -0.002 (-0.28%) 08-19 02:04
Open: 0.57 Pre. Close: 0.576
High: 0.5798 Low: 0.57
Volume: 64,107 Market Cap: 25(M)
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.59 - 0.59 0.59 - 0.59
Low: 0.57 - 0.57 0.57 - 0.57
Close: 0.57 - 0.58 0.58 - 0.58

Technical analysis

as of: 2022-08-18 3:54:07 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.71     One year: 0.75
Support: Support1: 0.55    Support2: 0.45
Resistance: Resistance1: 0.61    Resistance2: 0.64
Pivot: 0.57
Moving Average: MA(5): 0.58     MA(20): 0.57
MA(100): 0.6     MA(250): 1.37
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 26.3     %D(3): 33
RSI: RSI(14): 47
52-week: High: 3.82  Low: 0.45
Average Vol(K): 3-Month: 254 (K)  10-Days: 135 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LCI ] has closed above bottom band by 37.0%. Bollinger Bands are 67.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Thu, 18 Aug 2022
Base 2023 BMW X7 LCI With Just One Option Featured On Video - BMWBLOG

Thu, 18 Aug 2022
Is LCI Industries' (NYSE:LCII) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Simply Wall St

Thu, 18 Aug 2022
2024 BMW X5 M Virtually Drops by to Showcase LCI Goodies, Changes Are Subtle - autoevolution

Tue, 16 Aug 2022
LCI sees increased demand, but faces a shortage of airframes - Vertical Magazine

Tue, 16 Aug 2022
LCI Industries (NYSE:LCII) Shares Sold by State Board of Administration of Florida Retirement System - Defense World

Mon, 15 Aug 2022
Short Interest in LCI Industries (NYSE:LCII) Grows By 9.3% - Defense World

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 43 (M)
Shares Float 31 (M)
% Held by Insiders 13.4 (%)
% Held by Institutions 53 (%)
Shares Short 4,400 (K)
Shares Short P.Month 4,390 (K)

Stock Financials

EPS -7.9
EPS Est Next Qtl 0.66
EPS Est This Year 2.59
EPS Est Next Year 2.75
Book Value (p.s.) -3.93
Profit Margin (%) -85
Operating Margin (%) -13.8
Return on Assets (ttm) -4.5
Return on Equity (ttm) 0
Qtrly Rev. Growth -30.3
Gross Profit (p.s.) 2.33
Sales Per Share 8.65
EBITDA (p.s.) -0.36
Qtrly Earnings Growth 0
Operating Cash Flow 39 (M)
Levered Free Cash Flow 42 (M)

Stock Valuations

PE Ratio -0.08
PEG Ratio -0.1
Price to Book value -0.15
Price to Sales 0.06
Price to Cash Flow 0.63

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.